ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Inclusion Criteria

• •Age ≥ 18 years
• •Planned follow-up in cardio-oncology clinic as part of a baseline pre-treatment evaluation before a sequence of anthracycline and/or HER2-targeted therapy, according to the 2022 ESC recommendations
• •Inclusion regardless of prior exposure to potentially cardiotoxic anticancer therapies or thoracic radiotherapy